Table 4.
Decision criteria per treatment strategy at current period
| Decision criteria (Score 1–10) | Treatment Strategy | P | |||||
|---|---|---|---|---|---|---|---|
| A | B | C | |||||
| Median | IQR | Median | IQR | Median | IQR | ||
| Adjustment to patient’s peculiarities, principles / values & personal characteristics | 10 | (9–10) | 9 | (8–10) | 8 | (7–10) | < 0.01 |
| Simplicity and convenience of treatment regimen | 10 | (9–10) | 9 | (8–10) | 8 | (7–9) | < 0.01 |
| Compliance with International and Greek Guidelines for the management of DM-2 | 10 | (9–10) | 10 | (8–10) | 9 | (8–10) | < 0.01 |
| Choice due to corresponding physician’s clinical experience and / or familiarity | 10 | (9–10) | 9 | (8–10) | 9 | (8–10) | < 0.01 |
| Compliance with the specific administration indications of the formulations | 10 | (9–10) | 9 | (8–10) | 9 | (8–10) | < 0.02 |
| Compliance with Prescribing Guidelines from Regulatory Agencies or Insurance Funds | 10 | (8–10) | 9 | (8–10) | 9 | (8–10) | < 0.01 |
| Greater Efficacy of the specific treatment | 10 | (9–10) | 9 | (8–10) | 9 | (8–10) | < 0.02 |
| Greater Safety of the specific treatment | 10 | (9–10) | 9 | (8–10) | 9 | (8–10) | 0.01 |
| Better efficacy / safety combination with the specific treatment | 10 | (9–10) | 9 | (8–10) | 9 | (8–10) | < 0.01 |
| Pursuing the lowest possible cost for the patient | 10 | (8–10) | 8 | (7–10) | 8 | (6–9) | < 0.01 |
| Pursuing the lowest possible burden for Government Funds | 10 | (8–10) | 8 | (6–10) | 8 | (6–9) | < 0.01 |
| Better financial cost and clinical benefit (efficacy) ratio | 10 | (8–10) | 9 | (8–10) | 8 | (7–9) | < 0.01 |
| Minimization of adverse reactions from treatment | 10 | (9–10) | 9 | (8–10) | 9 | (8–10) | < 0.01 |